Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists

The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.

NCT Number	NCT07484061
Lead Sponsor	Olistic Research Labs S.L. Collaborators: Grupo Dermatologico Y Estetico Pedro Jaen S.A.
Conditions	Telogen Effluvium
Enrollment	40 participants
Start Date	2026-03-16
Primary Completion	2026-08-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-23